DMAA - NASDAQ
Drugs Made In America Acquisition Corp. Ordinary Shares
$10.61
+0.094%Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.
At a Glance
Live SnapshotDrugs Made In America Acquisition Corp. Ordinary Shares Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.
Asset Composition
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
Financial Health Insight
Conservative with tight liquidity: Low debt is positive, but current ratio warrants attention. Consider whether the company is efficiently deploying its equity capital.
Drugs Made In America Acquisition Corp. Ordinary Shares Balance Sheet
DMAA • NASDAQ
| Drugs Made In America Acquisition Corp. Ordinary Shares Balance Sheet | Dec 2025 | Dec 2024 |
|---|---|---|
ASSETS | ||
CURRENT ASSETS | ||
6.1K | 1.4K | |
6.1K | 1.4K | |
0.0 | 3.6K | |
6.1K | 0.0 | |
12.2K | 5K | |
NON-CURRENT ASSETS | ||
239.9M | 545.0 | |
239.9M | 545.0 | |
0.0 | -5K | |
239.9M | 550.0 | |
LIABILITIES | ||
CURRENT LIABILITIES | ||
222.2K | 0.0 | |
222.2K | 0.0 | |
154K | 77.0 | |
0.0 | 662.0 | |
0.0 | 56.0 | |
376.2K | 795.0 | |
NON-CURRENT LIABILITIES | ||
6.9M | 0.0 | |
6.9M | 0.0 | |
7.3M | 795.0 | |
SHAREHOLDERS' EQUITY | ||
239.9M | 985.0 | |
0.0 | 34.0 | |
-7.3M | -279.0 | |
0.0 | -985.0 | |
232.6M | -244.0 | |
232.6M | -244.0 | |
SUMMARY | ||
239.9M | 550.0 | |
0.0 | 662.0 | |
-6.1K | 660.0 | |
33,517,142 | 33,517,142 |
SEC Filings
DMAA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | April 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 01, 2026 | April 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 22, 2026 | 2026 | |
10-K 10-K 2025 FY FY | April 15, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2026 N/A | April 14, 2026 | April 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 08, 2026 | April 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 06, 2026 | February 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 06, 2026 | March 06, 2026 | 2026 |
Related Guides
Continue your DMAA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.